The approval came following months of debate within the medical circles over the procedures in recommending its use for the debilitating disease. We conducted one‐way deterministic sensitivity analyses using a priori feasible ranges around core parameter values. We conducted a threshold analysis of aducanumab costs to assess the cost at which the drug would meet our WTP threshold. We also assessed the threshold of annual moderate–severe AD costs above which aducanumab would be favorable at a cost of $56,000.
- A study by Salloway et al. reviewed the clinical and radiographic aspects of ARIA in both EMERGE and ENGAGE trials 49.
- Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect.
- While Aducanumab has been approved by FDA, there has been a major controversy over the clinical trials conducted to test the drug.
- According to the World Health Organisation (WHO), it is a syndrome in which there is deterioration in memory, thinking, behaviour and the ability to perform everyday activities.
- In the base case, aducanumab’s value-based price was $2000/y from a health care sector perspective and $3000/y from a societal perspective (Table 2).
Why was Biogen discontinued?
You can proceed with your request for details for Aduhelm (aducanumab-avwa) and access the medicine at full price based on the prescription of your physician. Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. In this model-based economic evaluation, we found that neither aducanumab nor donanemab is likely to be cost-effective by US standards at their expected prices of more than $25 000/y. To become cost-effective, aducanumab’s price would need to decrease to less than $3000/y; donanemab, in contrast, could be cost-effective at a price of $20 000/y. To assess our model’s external validity, we compared simulated outcomes with independent published estimates.
Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Given as an intravenous (into-the-vein) infusion once every four weeks, the treatment’s active ingredient, aducanumab, targets aggregated beta-amyloid, helping to reduce the buildup of amyloid plaques that contribute to nerve cell dysfunction and loss in Alzheimer’s. Food and Drug Administration (FDA) in 2021 to help slow neuronal loss and reduce the progression of cognitive and functional decline in individuals with Alzheimer’s. In June 2022, drug-maker Biogen announced it was withdrawing its submission from regulatory review by Health Canada.
At a time horizon of 30 years, the ICER was $128,520/QALY and at a time horizon of 3 years, the ICER was $731,660/QALY. At the upper bound of cost ($84,000) the ICER was $622,000/QALY and at the lower bound of cost ($33,600) it was $191,940/QALY. In threshold analysis, we estimate that the ICER for aducanumab would meet the WTP threshold at a drug cost of $22,820 (Figure 1). Annual costs for moderate–severe AD would have to be greater than $209,720 for aducanumab to be the favorable strategy at an annual cost of $56,000.
Model Validation
Agents that inhibit β-site amyloid precursor protein cleaving enzyme (BACE) (lanabecestat, elenbecestat, atabecestat, and verubecestat) have also been evaluated in individuals with mild to moderate AD and prodromal AD. The trials of BACE inhibitors have also failed to show clinical significance, and a trial was stopped due to safety concerns 56. The aducanumab saga has raged for almost 2 years, with the end perhaps still not in sight, and with time, its intricacies have grown to a level only surpassed by the pathologies and processes of the disease it treats. To estimate the cost-effectiveness of aducanumab and donanemab relative to standard care for early AD in the US. Aducanumab, which will be sold under the brand name of Aduhelm, is a monoclonal (referring to cloning of unique immunity cell) antibody that reduces amyloid-beta, which is a protein that leads to plaque formation in the brain. Plaque formation happens due to the accumulation of debris in the brain from neuron breakdown.
- Solving puzzles, learning new languages or new skills, and going out and making friends can all help.
- The study found that 425 of 1029 individuals (41.3%) developed ARIA during the placebo-controlled trial period, with 14 patients developing significant events (1.4%) 49.
- The interprofessional healthcare team should thoroughly educate and discuss aducanumab, its adverse effects, and therapy aims with patients and their caretakers.
- Once diagnosed after ruling out treatable causes of memory loss, there are usually four types of medications, including blood thinners for vascular blockages, and memory enhancing medicines (which do not increase memory power) to increase conduction between neurons.
US FDA okays Biogen Alzheimer’s drug
Hence, according to available data, patients with early-onset AD and MCI with clear β-amyloid plaques who are willing and able to undergo periodic follow-up with imaging studies such as PET and safety MRI and APOE4 genotype testing are good candidates for this drug. Infusion of aducanumab at a higher dose resulted in a modest slowing of cognitive decline among patients with mild cognitive impairment or early-onset AD dementia. Due to modest impact on cognition, the use of this drug by patients with AD will most likely be limited. The manufacturer is required to run an extended phase IIIb trial to verify the benefit of this drug. Access to therapy requires a careful selection of patients and periodic monitoring to ensure the optimal use of the drug. Knopman et al. published a critical review of the two aducanumab trials.16 The authors state that although it is possible that aducanumab has cognitive benefits, the available data are insufficient to make a “claim of efficacy” for the drug.
It is a serious neurodegenerative disease whose pathology is mainly driven by the deposition of amyloid-β (Aβ) plaques in the brain, accompanied by brain atrophy, synaptic dysfunction, neurodegeneration, and clinical dementia. In conclusion, our model suggests that aducanumab is likely not cost‐effective at an annual price of $56,000. In scenario sensitivity analyses (eTable 3 in the Supplement), aducanumab was not cost-effective under any scenario examined. Donanemab was cost-effective under several scenarios, with its value-based price exceeding $50 000/y only under the maximally optimistic scenario. Although many experts have reviewed the data from the aducanumab trials and published their commentaries based on this, the trial data have not been published in any peer-reviewed journal. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
If there is not more evidence in this phase that aducanumab is effective for treating symptoms of dementia, the drug might be pulled off the market. New medications start with FDA approval, and then get priced by its manufacturer, and then insurance companies determine coverage. Aduhelm was projected to have a large effect on Medicare’s spending due to its high price and large number of patients who aducanumab price in india qualify for treatment with mild to moderate Alzheimer’s symptoms. By conditionally providing coverage of the drug only in trials, it will make it accessible to thousands of people instead of the millions it was estimated to help.
New theory suggests Alzheimer’s might not be primarily a brain disease, could just be an autoimmune condition
Model states are represented by boxes; transitions between states are represented by arrows. Patients in each clinical stage have a monthly probability of transition to the next stage, denoted by rn; when receiving anti–amyloid antibody treatment, this probability is increased or decreased according to the efficacy of the treatment, denoted by H. Patients in all states are subject to an age- and stage-specific mortality probability; for clarity, these arrows are omitted from the diagram. Every 12 months, all surviving patients transition to the next age category, as represented by the horizontal arrows. This decision analytical model study evaluates the cost-effectiveness of aducanumab and donanemab for treatment of early Alzheimer disease in the US and estimates prices at which these agents would become cost-effective.
During infusion administration of aducanumab, the provider should be prepared and equipped in a setting with appropriate management in the event of hypersensitivity-like reactions. Another MRI should be obtained during the seventh infusion (first 10 mg/kg dosage) and the twelfth infusion (sixth 10 mg/kg dosage). A study by Salloway et al. reviewed the clinical and radiographic aspects of ARIA in both EMERGE and ENGAGE trials 49. The study found that 425 of 1029 individuals (41.3%) developed ARIA during the placebo-controlled trial period, with 14 patients developing significant events (1.4%) 49. We found that an indefinitely dosed treatment would not warrant a price of greater than $50 000/y, as was initially proposed for aducanumab, even if it slowed disease progression by 90%. In contrast, a limited-duration treatment akin to donanemab could provide good health economic value at $50 000/y if it slowed progression by a more achievable 50%.
(6) Data supported by randomization indicating that the low dose in Study 301 was numerically superior to the high dose despite none of the participants having received the 10 mg/kg dose. (7) The distribution of regional enrollment changing over the course of the studies may have confounded the impact of PV4, allowing the ApoE+ high dose to reach 10 mg/kg instead of only 6 mg/kg in earlier protocols. The reviewers concluded that there was no convincing evidence from available data that there was a delay in clinical progression of cognitive or functional decline from these studies. They noted that the single positive timepoint was un-replicated and conflicted by the second study. Additionally, the delayed start design with termination for futility did not help with the completeness or interpretability of long-term follow-up data in these studies.
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease
Given that few therapeutics achieve 100% effectiveness, this threshold will need to be re‐evaluated when data from an ongoing randomized clinical trial quantifies the clinical benefit of aducanumab. Individuals living with mild cognitive impairment due to Alzheimer’s or the mild dementia stage of Alzheimer’s disease may be eligible to switch to one of these treatments. Our findings suggest that at their current expected prices, neither aducanumab nor donanemab would be cost-effective for the treatment of early AD in the US. Although aducanumab’s price would need to fall to less than $3000/y to become cost-effective, donanemab—if its efficacy is confirmed in phase 3 trials—could be cost-effective when priced at $20 000/y. The provision of care would be constrained by the limited capacity of dementia specialists to evaluate and diagnose patients and by limited access to imaging sites to confirm the diagnosis of AD and infusion centres to deliver the treatment.
However, these effects have only been shown in people living with mild memory or thinking problems. The annual cost of $50,000 for aducanumab that has been suggested by market analysts would not be commensurate with its clinical benefits. Several anti-amyloid beta and anti-tau therapies have been evaluated or are currently under evaluation. Anti-β-amyloid therapies act by reducing the pathologic β-amyloid oligomers or by inhibiting β-amyloid plaque formation or by increasing clearance of β-amyloid peptides.